Advertisement

Topics

Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer

2015-02-12 20:17:39 | BioPortfolio

Published on BioPortfolio: 2015-02-12T20:17:39-0500

Clinical Trials [2326 Associated Clinical Trials listed on BioPortfolio]

Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

This phase II trial studies how well olaparib and cediranib maleate work in treating patients with ovarian, peritoneal, or fallopian tube cancer that has come back (recurrent). Olaparib an...

Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

RATIONALE: Cediranib maleate and cilengitide may stop the growth of tumor cells by blocking blood flow to the tumor. Giving cediranib maleate together with cilengitide may kill more tumor ...

Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies

This phase I trial studies the side effects and best dose of cediranib maleate and selumetinib in treating patients with solid malignancies. Cediranib maleate and selumetinib may stop the ...

Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies

This phase I trial studies the side effects and best dose of cediranib maleate and selumetinib in treating patients with solid malignancies. Cediranib maleate and selumetinib may stop the ...

Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer

This partially randomized phase I/II trial studies the side effects and best dose of cediranib maleate when given together with or without lenalidomide and to see how well they work in tre...

PubMed Articles [17438 Associated PubMed Articles listed on BioPortfolio]

Evaluation of complete blood count parameters to predict endometrial cancer.

Complete blood count parameters have been introduced to be diagnostic biomarkers for many cancer-related diseases associated with inflammatory process. The aim of our study was to detect whether there...

Population exposure-safety analysis of cediranib for Phase I and II studies in patients with cancer.

Risk reduction of endometrial and ovarian cancer after bisphosphonates use: A meta-analysis.

Recent epidemiological studies have investigated the associations between the use of bisphosphonates and the development of endometrial cancer and ovarian cancer; these studies have shown controversia...

HRCT texture analysis for pure or part-solid ground-glass nodules: distinguishability of adenocarcinoma in situ or minimally invasive adenocarcinoma from invasive adenocarcinoma.

To distinguish between adenocarcinoma in situ (AIS)-minimally invasive adenocarcinoma (MIA) and invasive adenocarcinoma (IAC) showing pure or part-solid ground-glass nodules (GGNs) by high-resolution ...

Complete Histologic Regression of Endometrioid Adenocarcinoma on Endometrial Biopsy After Progestin Treatment Does Not Guarantee the Regression of an Invasive Carcinoma Within the Myometrium.

Currently, the indications for progestin therapy are limited to endometrioid adenocarcinoma that are International Federation of Gynecology and Obstetrics (FIGO) grade 1, FIGO stage IA, and confined t...

Medical and Biotech [MESH] Definitions

An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.

Neoplasms of the endometrial stroma that sometimes involve the MYOMETRIUM. These tumors contain cells that may closely or remotely resemble the normal stromal cells. Endometrial stromal neoplasms are divided into three categories: (1) benign stromal nodules; (2) low-grade stromal sarcoma, or endolymphatic stromal myosis; and (3) malignant endometrial stromal sarcoma (SARCOMA, ENDOMETRIAL STROMAL).

A lesion with cytological characteristics associated with invasive adenocarcinoma but the tumor cells are confined to the GLANDULAR EPITHELIAL CELLS of origin. Adenocarcinoma in situ of the CERVIX and the LUNG are the most common.

A pharmaceutical preparation of brimonidine tartrate and timolol maleate. The combined ADRENERGIC ALPHA2 RECEPTOR AGONIST and ADRENERGIC BETA-ANTAGONIST activity of these drugs reduce INTRAOCULAR PRESSURE in GLAUCOMA patients.

The extension of endometrial tissue (ENDOMETRIUM) into the MYOMETRIUM. It usually occurs in women in their reproductive years and may result in a diffusely enlarged uterus with ectopic and benign endometrial glands and stroma.

More From BioPortfolio on "Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial